US vaccine hopeful of using Gates Foundation cash to prepare for human trial | World News - Hindustan Times
close_game
close_game

US vaccine hopeful of using Gates Foundation cash to prepare for human trial

Reuters |
Jan 29, 2021 06:01 PM IST

Harvard University scientist Luk Vandenberghe and University of Pennsylvania gene therapy head James Wilson said primate safety and efficacy tests have proven promising for their single-dose candidate, targeted for room-temperature storage.

Scientists who normally focus on fixing defective genes said on Friday that up to $2.1 million from the Bill & Melinda Gates Foundation will help them move their Covid-19 vaccine candidate toward 2021 human trials.

Their candidate relies on an adeno-associated virus (AAV), deemed harmless to humans, to deliver DNA fragments from the new coronavirus, telling human cells to make a protein that provokes an immune response. (Representative Image)(AP)
Their candidate relies on an adeno-associated virus (AAV), deemed harmless to humans, to deliver DNA fragments from the new coronavirus, telling human cells to make a protein that provokes an immune response. (Representative Image)(AP)

Harvard University scientist Luk Vandenberghe and University of Pennsylvania gene therapy head James Wilson said primate safety and efficacy tests have proven promising for their single-dose candidate, targeted for room-temperature storage.

Hindustan Times - your fastest source for breaking news! Read now.

"We believe there is real potential," Vandenberghe said in an interview. "That being said, we're not naive. There's 300 vaccines racing towards the door and biology is complex."

Their candidate relies on an adeno-associated virus (AAV), deemed harmless to humans, to deliver DNA fragments from the new coronavirus, telling human cells to make a protein that provokes an immune response.

AAVs are already used in gene therapies sold by Novartis, including its $2.1 million-per-patient Zolgensma for spinal muscular atrophy. The Swiss company's gene therapy unit is backing the project with technical assistance and supply.

Other Covid-19 vaccines use viral vectors, too, though AstraZeneca and Oxford University's shot, Russia's Sputnik V and Johnson & Johnson's one-dose candidate rely on so-called adenoviruses to transport coronavirus DNA.

Gates Foundation money will support more pre-clinical tests ahead of a overseas safety trial in a still-undisclosed location where vaccines are not broadly available, Vandenberghe, who runs Mass General Brigham hospital's Grousbeck Gene Therapy Center in Boston, said.

Though previously unused in approved vaccines, he is optimistic AAVs will be safe, since only tiny amounts are needed compared to what is required for gene therapies that have been given to many patients.

While he predicts every approved Covid-19 vaccine dose available through 2022 will see use, Vandenberghe acknowledged his group's success also hinges on finding a deep-pocketed partner with vaccine experience to bankroll large-scale production.

"We've already invested more than $10 million," he said. "If indeed we want to meet the time lines we were just talking about, this needs a commercial larger vaccine player to be accelerated, like an AstraZeneca for Oxford's."

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away! - Login Now!

Get Latest World News along with Latest News from India at Hindustan Times.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On